Table 1.
Patient characteristics and findings
| N | 50 | FH of HCM, n (%) | 19 (38) |
|---|---|---|---|
| Male gender, n (%) | 37 (74) | CMR findings | |
| Age, years | 46.9 ± 11.7 | LV EDV, ml/m2 | 78.7 ± 13.1 |
| Height, cm | 171.2 ± 9.0 | LV EF, % | 62.3 ± 5.9 |
| Weight, kg | 81.7 ± 14.6 | LV Mass, g/m2 | 72.8 ± 26.3 |
| Body mass index, kg/m2 | 27.7 ± 3.7 | LAV, ml/m2 | 59.3 ± 13.5 |
| Systolic blood pressure, mmHg | 125.5 ± 17.6 | LGE, n (%) | 35 (70) |
| Diastolic blood pressure, mmHg | 74.5 ± 12.5 | Medications | |
| Heart rate | 60.6 ± 10.2 | Beta blocker, n (%) | 24 (48) |
| Echocardiography | CC blocker, n (%) | 8 (16) | |
| Maximum wall thicknessa (mm) | 19.3 ± 4.9 | Disopyramide, n (%) | 4 (8) |
| LVOT obstruction, n (%) | 11 (22) | Diuretic, n (%) | 2 (4) |
| Resting LVOT gradient, mmHg | 68.5 ± 40.0 |
CC calcium channel, EDV end diastolic volume indexed to body surface area, EF ejection fraction, FH family history, LAV left atrial volume indexed to body surface area, LGE late gadolinium enhancement, LV left ventricle, LVOT left ventricular outflow tract
aIn 5 subjects with apical or localized lateral hypertrophy maximum wall thickness is taken from CMR